Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00994591 · ClinicalTrials.gov registry record · Phase 1

Cotinine Metabolism in Infants and Children

A Phase 1 study, sponsored by University of California, San Francisco.

Completed
Registry status
Phase 1
Development phase
56
Enrollment target

NCT00994591 is a Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 56 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00994591, a Phase 1 study, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
Phase 1
Development phase
56 participants
Enrollment target

Study Summary

Levels of cotinine, a biomarker for nicotine, have been found to be higher in infants and small children than adults. This pharmacokinetic study is designed to determine whether children metabolize cotinine differently than adults. Seventy-two healthy children between the ages of 2 months and 6 years will come with their mothers to SFGH GCRC for one approximately 9 hour visit. After being examined by a pediatrician, the child will be administered one dose of cotinine at .05 mg/kg. Saliva and urine samples will be collected prior to dosing and throughout the day to characterize the metabolism and excretion of cotinine. The investigators have previously shown that a ratio of 3'-hydroxycotinine/cotinine (3HC/Cot) in saliva correlates closely to nicotine metabolism. Following these one day hospital visits, a research assistant will visit the participants in their homes to collect urine and saliva samples at 1,2,3,7, and 10 days after the initial dose.

Interventions

  • DRUG Pharmacokinetic dosing

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 2007-01
Est. Completion 2011-06
Phase Phase 1

What the Registry Record Tells You About NCT00994591

The ClinicalTrials.gov registry entry for NCT00994591 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Pharmacokinetic dosing is the first listed.

NCT00994591 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00994591 about?

NCT00994591 is a clinical study titled "Cotinine Metabolism in Infants and Children". Levels of cotinine, a biomarker for nicotine, have been found to be higher in infants and small children than adults. This pharmacokinetic study is designed to determine whether children metabolize cotinine differently than adults. Seventy-two healthy children between the ages of 2 months and 6 yea...

What is the current status of trial NCT00994591?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2007-01. Estimated completion is 2011-06.

What interventions are being tested in trial NCT00994591?

The interventions under investigation include: Pharmacokinetic dosing (DRUG).

Who is sponsoring clinical trial NCT00994591?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.